NCT03554291View on ClinicalTrials.gov

Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

July 11, 2023

Study Completion Date

July 11, 2023

Conditions
Pulmonary Arterial HypertensionRight Heart Failure
Interventions
DRUG

Famotidine 20 MG

Famotidine 20 mg capsule taken daily for 24 weeks.

OTHER

Placebo

Placebo capsule taken daily for 24 weeks.

Trial Locations (1)

98195

University of Washington Medical Center, Seattle

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Washington

OTHER

NCT03554291 - Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension | Biotech Hunter | Biotech Hunter